Graf Akcie CLDX (Celldex Therapeutics Inc.). Diskuze k akciím CLDX. Aktuální informace CLDX.

Základní informace o společnosti Celldex Therapeutics Inc. (Akcie CLDX)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 1.86B
Hodnota podniku (EV) 2.26B
Tržby 8.618M
EBITDA -50.13
Zisk -66.04
Růst v tržbách Q/Q 1,374.58 %
Růst v tržbách Y/Y 96.00 %
P/E (Cena vůči ziskům) N/A
Forward P/E -136.21
EV/Sales 261.97
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 215.26
P/FCF N/A
Price/Book 8.86
Účetní hodnota na akcii 5.28
Hotovost na akcii 4.91
FCF vůči ceně -2.60 %
Počet zaměstnanců 124
Tržba na zaměstnance 69.500k
Profit margin -805.88 %
Operating margin -786.50 %
Gross margin 100.00 %
EBIT margin -777.14 %
EBITDA margin -581.63 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -32.00 %
EPS - Očekávaný růst příští rok 2.78 %
Return on assets -28.86 %
Return on equity -32.38 %
ROIC -33.98 %
ROCE -35.24 %
Dluhy/Equity 0.13
Čistý dluh/EBITDA 14.38
Current ratio 11.57
Quick Ratio 11.57
Volatilita 5.14
Beta 1.14
RSI 34.77
Cílová cena analytiků 26
Známka akcie (dle analytiků) 1.00
Insider ownership 4.55 %
Institutional ownership 78.23 %
Počet akcií 46.482M
Procento shortovaných akcií 9.32 %
Short ratio 4.16 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 1986
Země United States

Finanční výsledky akcie CLDX

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$3.573$9.538$12.743$6.786$5.48$3.586
Cost Of Goods Sold------
Gross Profit$3.573$9.538$12.743$6.786$5.48$3.586
Research And Development Expenses$42.672$66.449$96.171$102.726$100.171$104.381
SG&A Expenses$15.426$19.269$25.003$35.979$33.837$20.622
Other Operating Income Or Expenses$-0.506$10.944$-12.2---
Operating Expenses$58.604$165.974$134.27$139.702$135.021$126.016
Operating Income$-55.031$-156.436$-121.527$-132.916$-129.541$-122.43
Total Non-Operating Income/Expense$4.153$4.487$4.214$4.386$2.344$4.35
Pre-Tax Income$-50.878$-151.949$-117.313$-128.53$-127.197$-118.08
Income Taxes-$-0.765$-24.282---
Income After Taxes$-50.878$-151.184$-93.031$-128.53$-127.197$-118.08
Other Income------
Income From Continuous Operations$-50.878$-151.184$-93.031$-128.53$-127.197$-118.08
Income From Discontinued Operations------
Net Income$-50.878$-151.184$-93.031$-128.53$-127.197$-118.08
EBITDA$-51.313$-62.707$-116.507$-127.898$-125.18$-118.934
EBIT$-55.031$-156.436$-121.527$-132.916$-129.541$-122.43
Basic Shares Outstanding15109766
Shares Outstanding15109766
Basic EPS$-3.51$-14.48$-10.86$-18.99$-19.64$-19.79
EPS - Earnings Per Share$-3.51$-14.48$-10.86$-18.99$-19.64$-19.79
# 2020 2019 2018 2017 2016 2015
Current Ratio5.72867.86225.21915.55239.75328.3698
Long-term Debt / Capital------
Debt/Equity Ratio--0.02780.0182--
Gross Margin100100100100100100
Operating Margin-1540.19-1640.134-953.6766-1958.68-2363.887-3414.111
EBIT Margin-1540.19-1640.134-953.6766-1958.68-2363.887-3414.111
EBITDA Margin-1436.132-657.4438-914.2824-1884.733-2284.307-3316.62
Pre-Tax Profit Margin-1423.957-1593.091-920.6074-1894.047-2321.113-3292.805
Net Profit Margin-1423.957-1585.07-730.0557-1894.047-2321.113-3292.805
Asset Turnover0.02910.06120.04040.01770.01620.0145
Inventory Turnover Ratio------
Receiveable Turnover3.52023.01646.77823.80385.64958.3981
Days Sales In Receivables103.6874121.003353.849295.956464.607743.4621
ROE - Return On Equity-54.1105-121.8637-39.3584-48.4231-43.8452-55.7876
Return On Tangible Equity-112.2243-200.5891-119.5741-138.2519-48.8569-65.278
ROA - Return On Assets-41.3868-97.0316-29.4753-33.5274-37.6786-47.6102
ROI - Return On Investment-54.1106-121.8636-39.3584-48.4231-43.8452-55.7876
Book Value Per Share5.540110.374625.594933.0244.073135.4192
Operating Cash Flow Per Share4.00554.45565.0385-1.4231.752-4.311
Free Cash Flow Per Share4.00164.61915.2363-1.07611.3222-3.8456